Recent developments for new investigational JAK inhibitors in psoriatic arthritis
ABSTRACT Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting
about one-third of subjects with psoriasis. Several treatment modalities targeting Janus …
about one-third of subjects with psoriasis. Several treatment modalities targeting Janus …
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic …
M Cardner, D Tuckwell, A Kostikova, P Forrer… - RMD open, 2023 - rmdopen.bmj.com
Objectives Despite several effective targeted therapies, biomarkers that predict whether a
patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently …
patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently …
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the …
G Schett, W Chen, S Gao, SD Chakravarty… - Arthritis Research & …, 2023 - Springer
Background Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19
subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating …
subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating …